Literature DB >> 6342756

Mechanisms of immunological eradication of a syngeneic guinea pig tumor: participation of a component(s) of recipient origin in the expression of systemic adoptive immunity.

S Shu, L S Fonseca, H Kato, B Zbar.   

Abstract

The effects of carrageenan and trypan blue on the expression of adoptive immunity to the syngeneic guinea pig line 10 hepatoma were investigated. Adoptive immunity was assessed by observing dermal tumor growth in recipients of immune cells and by bioassays in which tumor challenge sites were transplanted into secondary hosts. Carrageenan abrogated transferred immunity in treated animals as evidenced by dermal tumor growth and by development of fatal ascites tumors in peritoneal cavities of the secondary hosts. Trypan blue, on the other hand, did not abrogate transferred immunity in treated animals. However, the i.p. bioassay revealed the presence of line 10 cells in the tumor challenge sites 10 days after adoptive transfer. In vitro and in vivo exposure of immune spleen cells to carrageenan or trypan blue had no significant effect on the subsequent adoptive transfer, indicating that the inhibitory activity of these agents cannot be attributed to direct toxicity to immune lymphoid cells. Tumor challenge sites taken from carrageenan or trypan blue-treated animals 5 days after adoptive transfer failed to grow progressively when transplanted s.c. into secondary hosts. This observation suggests the presence of immune cells at tumor challenge sites. Thus, the inhibitory effects were unlikely due to interference with recirculation of the i.v.-transferred immune cells. Adoptive immunity was not influenced in guinea pigs that received a lethal dose of irradiation (500 rads). These results demonstrate that a recipient component(s) sensitive to carrageenan and trypan blue but resistant to radiation is essential to the expression of adoptive immunity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6342756

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Springer Semin Immunopathol       Date:  1986

2.  Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.

Authors:  M P Colombo; M Parenza; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Major histocompatibility complex class II antigen expression on leucocyte subpopulations in the draining lymph node and tumour in the early phase of bacillus-Calmette-Guérin-induced tumour regression.

Authors:  P A Steerenberg; W H De Jong; E Geerse; A De Graaf; R J Scheper; W Den Otter; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Major-histocompatibility-complex-class-II-positive cells and interleukin-2-dependent proliferation of immune T cells are required to reject carcinoma cells in the guinea pig.

Authors:  P A Steerenberg; W H De Jong; E Geerse; A Beuvink; R J Scheper; W Den Otter; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.

Authors:  L T Balemans; V Mattijssen; P A Steerenberg; B E Van Driel; P H De Mulder; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

6.  Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin.

Authors:  P A Steerenberg; W H De Jong; E Geerse; B J Aleva; C M Besselink; B T Van Rens; V P Rutten; L G Poels; R J Scheper; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.

Authors:  K Ando; T Moriyama; L G Guidotti; S Wirth; R D Schreiber; H J Schlicht; S N Huang; F V Chisari
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.